CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
by Zacks Equity Research
Ligand (LGND) first-quarter earnings and sales decrease year over year.